← Back to Clinical Trials
Recruiting NCT05263596

NCT05263596 SARCOPEDIA - Sarcopenia Diagnostics in Aging Medicine

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05263596
Status Recruiting
Phase
Sponsor University Department of Geriatric Medicine FELIX PLATTER
Condition Sarcopenia
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2022-07-11
Primary Completion 2024-10-30

Trial Parameters

Condition Sarcopenia
Sponsor University Department of Geriatric Medicine FELIX PLATTER
Study Type INTERVENTIONAL
Phase N/A
Enrollment 120
Sex ALL
Min Age 65 Years
Max Age N/A
Start Date 2022-07-11
Completion 2024-10-30
Interventions
dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Musculoskeletal aging is one of the major responsibilities and challenges for public health. In particular, sarcopenia correlates with an increased risk of falls and increased morbidity and mortality. With regard to screening for sarcopenia, the guidelines of the European Working Group on Sarcopenia in Older People (EWGSOP2) refer to algorithmic case finding, diagnosis, and quantification of the severity of sarcopenia in clinical. While functional measurements are more difficult to standardize and associated with higher variability, Dual-energy X-ray absorptiometry (DXA) is considered a highly accurate method, even referred to as the "gold standard" to determine muscle mass in the scientific literature. Nevertheless, DXA, which is routinely used, shows inconsistent correlation with functional decline in muscle strength. Another method of muscle quantification is bioelectrical impedance analysis (BIA), a simple, portable instrument that is more readily available and applicable due to its lower cost. However, it tends to overestimate muscle mass and is also more susceptible to a person's hydration status. Because of these difficulties, recent research has focused on the potential of using shear wave elastography. This method indirectly serves to quantify the rapid type II muscle fibers in order to make statements about the muscle quality because an age-related decrease in type II muscle fibers is associated with a more frequent fall frequency. First, the investigators will define three different categories according to the EWGSOP 2 guidelines based on the muscle strength (grip strength, assessed by pneumatic hand dynamometer) and muscle mass (Appendicular skeletal muscle mass, assessed by BIA): "No Sarcopenia", "Probable Sarcopenia" and "Confirmed Sarcopenia". Within these categories, the Investigators would like to establish a multivariate data analysis of different functional measurements with quantitative imaging results. This exploratory trial design is intended to improve understanding within the three categories and to test proxy measurements of different patients who are ruled out for common routine measurements due to, for example, cognitive impairment or pre-existing rheumatic disease. This is essential to consider the heterogeneity of the aging society proportionally.

Eligibility Criteria

Inclusion Criteria: The investigators aim to include patients ≥ 65 years old newly admitted for study eligibility at the UAFP. Exclusion Criteria: * Lack of informed written consent * Implanted defibrillation device * Implanted pacemaker * Acute sepsis or severe volume overload * Life expectancy of \< 3 months according to treating doctor * bedridden * Plasters or bandages that cannot be removed from the feet or hands * Isolated patients (contact and aerosol) * Measurement is not possible due to organizational reasons * Inability to follow the procedures, e.g. due to language problems, psychological disorders

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology